Aldeyra Therapeutics Toekomstige groei

Future criteriumcontroles 5/6

Aldeyra Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 71.6% en 55.5% per jaar. De winst per aandeel zal naar verwachting groeien met 72% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -17.4% zijn.

Belangrijke informatie

71.6%

Groei van de winst

72.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	55.5%
Toekomstig rendement op eigen vermogen	-17.4%
Dekking van analisten	Good
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Winst- en omzetgroeiprognoses

NasdaqCM:ALDX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	57	-14	-40	N/A	5
12/31/2025	65	-4	-62	N/A	8
12/31/2024	N/A	-54	-47	N/A	8
9/30/2024	N/A	-45	-31	-31	N/A
6/30/2024	N/A	-38	-31	-31	N/A
3/31/2024	N/A	-30	-31	-31	N/A
12/31/2023	N/A	-38	-30	-30	N/A
9/30/2023	N/A	-46	-42	-42	N/A
6/30/2023	N/A	-52	-47	-47	N/A
3/31/2023	N/A	-61	-53	-53	N/A
12/31/2022	N/A	-62	-57	-57	N/A
9/30/2022	N/A	-65	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-63	-42	-42	N/A
12/31/2021	N/A	-58	-43	-43	N/A
9/30/2021	N/A	-53	-39	-39	N/A
6/30/2021	N/A	-46	-37	-37	N/A
3/31/2021	N/A	-39	-36	-36	N/A
12/31/2020	N/A	-38	-37	-37	N/A
9/30/2020	N/A	-39	-40	-40	N/A
6/30/2020	N/A	-49	-42	-42	N/A
3/31/2020	N/A	-55	-48	-48	N/A
12/31/2019	N/A	-61	-45	-45	N/A
9/30/2019	N/A	-58	-42	-42	N/A
6/30/2019	N/A	-50	-41	-41	N/A
3/31/2019	N/A	-46	-35	-35	N/A
12/31/2018	N/A	-39	-30	-30	N/A
9/30/2018	N/A	-35	-27	-27	N/A
6/30/2018	N/A	-29	N/A	-24	N/A
3/31/2018	N/A	-26	N/A	-23	N/A
12/31/2017	N/A	-22	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-18	N/A
6/30/2017	N/A	-20	N/A	-17	N/A
3/31/2017	N/A	-19	N/A	-15	N/A
12/31/2016	N/A	-19	N/A	-15	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
6/30/2016	N/A	-17	N/A	-14	N/A
3/31/2016	N/A	-15	N/A	-12	N/A
12/31/2015	N/A	-12	N/A	-9	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-9	N/A	-6	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-10	N/A	-5	N/A
9/30/2014	N/A	-6	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-3	N/A
3/31/2014	N/A	5	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ALDX de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat ALDX de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ALDX binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ALDX ( 55.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ALDX ( 55.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ALDX binnen 3 jaar verliesgevend zal zijn.

Aldeyra Therapeutics Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.1% to US$10.00

Consensus EPS estimates fall by 209%

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA